


Department of Biology presents

**“Harnessing Immune System Proteins for the Treatment of Cancer and Infectious Disease”**



**ABSTRACT.** The past decade has witnessed an explosion in the use of therapeutic antibodies for treating a variety human disease. A series of stunning successes in the clinic has resulted in a multi-billion dollar industry. The Brooks lab employs structural biology to better understand how therapeutic antibodies interact with their targets with the hope of designing better antibody drugs. Specifically, we are looking at two major classes of antibody therapeutics: (1) Nanobodies, a class of single domain antibodies for the neutralization of Listeria invasion; (2) AR20.5, a murine monoclonal antibody that is being developed by Quest Pharmatech Inc. for the treatment of pancreatic cancer. Using X-ray crystallography combined with binding studies we have elucidated the mechanism of action of both these classes of therapeutics.

**Dr. Cory Brooks**  
**Department of Chemistry, Fresno State**

**Friday, September 9, 2016**  
**3:00 PM**  
**Science 2, Room 109**

**For further information:** [www.csufresno.edu/biology](http://www.csufresno.edu/biology) or phone 278-2001. If you need a disability-related accommodation or wheelchair access information, please contact Lindasue Garner at the Department of Biology @ 278-2001 or e-mail [lgarner@csufresno.edu](mailto:lgarner@csufresno.edu) (at least one week in advance of event).